Raltegravir in the management of HIV-infected patients

Drug Design, Development and Therapy

Volumn , Issue 2, 2008, Pages 281-288

  Stellbrink, Hans Jürgen ^a  

^a Infektionsmedizinisches Centrum Hamburg   (Germany)

Author keywords

HAART; HIV infection; Integrase inhibitor; MK 0518; Raltegravir

Indexed keywords

AMINO ACID; ANTICONVULSIVE AGENT; ANTILIPEMIC AGENT; ATAZANAVIR; CONTRACEPTIVE AGENT; CYTOCHROME P450; DOUBLE STRANDED DNA; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; GENOMIC RNA; GLUCURONOSYLTRANSFERASE 1A1; INDINAVIR; INTEGRASE; LAMIVUDINE; MARAVIROC; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RIFAMPICIN; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS RNA;

AMINO ACID SUBSTITUTION; AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANTIBIOTIC SENSITIVITY; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CD4+ T LYMPHOCYTE; CELL COUNT; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG EXPOSURE; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG URINE LEVEL; FATIGUE; GENE INSERTION; GENETIC VARIABILITY; GLUCURONIDATION; HEADACHE; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IN VITRO STUDY; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; MUTAGENESIS; MUTATION; MYALGIA; MYOPATHY; NAUSEA; PHARYNGITIS; PLASMA PROTEIN BINDING; RASH; REVERSE TRANSCRIPTION; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; STEADY STATE; TREATMENT FAILURE; TREATMENT RESPONSE; VIREMIA; VIRUS ENTRY; VIRUS ISOLATION; VIRUS LOAD;

EID: 77953667778     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/dddt.s3337     Document Type: Review

References (36)

1. Anderson MS, Wenning LA, Moreau A, et al. 2007, Effect of raltegravir (RAL) on the pharmacokinetics (PK) of oral contraceptives [abstract]. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 17-20 September 2007, Chicago, IL, USA abstract A-1425. 2007.
2. Cooper DA, Gatell J, Rockstroh J, et al. 2007. Results of BENCHMRK-1, a Phase III study evaluating the efficacy and safety of MK-0518, a Novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus [abstract]. 14th Conf Retro Opportun Infect Los Angeles abstract 105aLB.
3. Cooper DA, Steigbigel RT, Gatell JM, et al. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med, 359:355-365
4. Craigie R. 2001. HIV integrase, a brief overview from chemistry to therapeutics. J Biol Chem, 276:23213-23216 (Pubitemid 37410700)
5. DeJesus E, Cohen C, Elion R, et al. 2007. First report of raltegravir (RAL, MK-0518) use after virologic rebound on elvitegravir (EVT, GS 9137) [abstract]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, 22-25, July 2007; Abstract TUPEB032. 2007.
6. Embrey MW, Wai JS, Funk TW, et al. 2005. A series of 5-(5,6)- dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells. Bioorg Med Chem Lett, 15:4550-4554
7. Espeseth AS, Felock P, Wolfe A, et al. 2000. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci U S A, 97:11244-11249
8. Goethals O, Clayton R, Wagemans E, et al. 2008. Resistance mutations in HIV-1 integrase selected with raltegravir or elvitegravir confer reduced susceptibility to a diverse panel of integrase inhibitors [abstract]. XVII International HIV Drug Resistance Workshop June 10-14, 2008 Sitges, Spain abstract no. 2008.
9. Grinsztejn B, Nguyen BY, Katlama C, et al. 2007. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet, 369:1261-1269 (Pubitemid 46553846)
10. Harris M, Larsen G, Montaner JS. 2008a. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS, 22:1890-1892
11. Harris M, Larsen G, Montaner JS. 2008b. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. Aids, 22:1224-1226
12. Hazuda D, Blau CU, Felock P, et al. 1999. Isolation and characterization of novel human immunodeficiency virus integrase inhibitors from fungal metabolites. Antivir Chem Chemother, 10:63-70. (Pubitemid 29158682)
13. Hazuda D, Miller MD, Nguyen BY, et al. 2007. Resistance to the HIV-integrase inhibitor raltegravir: analysis of Protocol 005, a Phase 2 study in patients with triple-class resistant HIV-1 infection [abstract]. Antivir Ther, abstract no.8[12], S10.
14. Hazuda DJ, Anthony NJ, Gomez RP, et al. 2004. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci U S A, 101:11233-11238
15. Hazuda DJ, Felock P, Witmer M, et al. 2000. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science, 287:646-650 (Pubitemid 30070911)
16. Iwamoto M, Kassahun K, Troyer MD, et al. 2008a. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol, 48:209-214
17. Iwamoto M, Wenning LA, Liou SY, et al. 2006a. Rifampin (RIF) modestly reduces plasma levels of MK-0518 [abstract]. 8th international congress on drug therapy in HIV infection, Glasgow, United Kingdom, November 12-16, 2006; abstract P299.
18. Iwamoto M, Wenning LA, Petry AS, et al. 2006b. Minimal effect of ritonavir (RTV) and efavirenz (EFV) on the pharmacokinetics (PK) of MK-0518 [abstract]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2006; San Francisco, USA abstract A-373.
19. Iwamoto M, Wenning LA, Petry AS, et al. 2008b. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther, 83:293-299
20. Kassahun K, McIntosh I, Cui D, et al. 2007. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos, 35:1657-1663 (Pubitemid 47296061)
21. Kassahun K, McIntosh I, Hreniuk D, et al. Absorption, metabolism and excretion of MK-0518, a potent HIV-1 integrase inhibitor, in healthy male volunteers [abstract]. 46th Interscience Conference on 1 Agents and Chemotherapy; September 27-30, 2006; San Francisco, USA abstract A-372.
22. Lafemina RL, Schneider CL, Robbins HL, et al. 1992. Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J Virol, 66:7414-7419
23. Malet I, Delelis O, Valantin MA, et al. 2008. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother, 52:1351-1358 (Pubitemid 351521998)
24. Markowitz M, Nguyen BY, Gotuzzo E, et al. 2008. Sustained antiretroviral efficacy of raltegravir as part of combination ART in treatment-naive HIV-1 infected patients: 96-week data [abstract]. 17th International AIDS Conference; August 3-8, 2008; Mexico City, Mexico Abstract TUAB0102.
25. Markowitz M, Nguyen BY, Gotuzzo E, et al. 2007. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr, 46:125-133 (Pubitemid 47482607)
26. Merck and Co., W. S. N. 0. U. IsentressTM FDA Briefing Document. Food And Drug Administration Homepage. 2007. www.fda.gov/ohmrs/ dockets/ac/07/briefing/ 2007-4314b1-01-Merck.pdf.
27. Merck and Co., W. S. N. 0. U. IsentressTM Prescribing Information. US Food and Drug Administration Homepage. 2008. www.fda.gov/cder/foi/label/2007/ 0221451b1.pdf.
28. Mistry G, Wenning L, Petry Aet al. 2007. Atazanavir modestly increases plasma leves of MK-0518 [abstract]. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, 22-25, July 2007; abstract 1985.
29. Murray JM, Emery S, Kelleher AD, et al. 2007.Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase/Aids, 21:2315-2321
30. Pais GC, Zhang X, Marchand C, et al. 2002. Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. J Med Chem, 45:3184-3194 (Pubitemid 34774270)
31. Roquebert B, Damond F, Collin G, et al. on behalf of the French ANRS HIV- 2008. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvite-gravir in vitro. J Antimicrob Chemother, DOI 10.1093/jac/dkn335.
32. Sedaghat AR, Dinoso JB, Shen L, et al. 2008. Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci U S A, 105:4832-4837 (Pubitemid 351753832)
33. Steigbigel R, Kumar P, Eron J, et al. 2007. Results of BENCHMRK-2, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus [abstract]. 14th Conf Retro Opportun Infect Los Angeles abstract 105bLB.
34. van Baelen K, van Eygen V, Rondelez E, et al. 2008. Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility Aids, Epub ahead of print.
35. Wenning LA, Friedman E, Kost JT, et al. 2006a. Lack of a significant drug interaction between MK-0518 and tenofovir disoproxil fumarate (TDF) [abstract]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2006; San Francisco, USA abstract A-375.
36. Wenning LA, Hanley H, Stone J, et al. 2006b. Effect of tipranavir + ritonavir (TPV + RTV) on pharmacokinetics of MK-0518 [abstract]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2006; San Francisco, USA abstract A-374. 2006b.